尼妥珠单抗，一种有前景的治疗上皮来源肿瘤的治疗性单克隆抗体。
Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin.
机构信息
Biocon Limited, Bangalore, India.
出版信息
MAbs. 2009 Jan-Feb;1(1):41-8. doi: 10.4161/mabs.1.1.7509.
Abstract
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR). Clinical trials are ongoing globally to evaluate nimotuzumab in different indications. Nimotuzumab has been granted approval for use in squamous cell carcinoma of head and neck (SCCHN), glioma and nasopharyngeal cancer in different countries. This review focuses on the unique functional characteristics of nimotuzumab. Also, it discusses the safety and efficacy data obtained from the Phase IIb clinical trial conducted in India in SCCHN. Post marketing surveillance data from Cuba for the use of nimotuzumab in pediatric and adult glioma is also discussed. Overall, nimotuzumab has immense therapeutic potential in cancers of epithelial origin.
摘要
尼妥珠单抗是一种针对表皮生长因子受体（EGFR）的人源化治疗性单克隆抗体。目前正在全球范围内开展临床试验，以评估尼妥珠单抗在不同适应症中的疗效。尼妥珠单抗已在多个国家获得批准，可用于治疗头颈部鳞状细胞癌（SCCHN）、脑胶质瘤和鼻咽癌。本文重点介绍了尼妥珠单抗的独特功能特性，并讨论了在印度开展的针对 SCCHN 的 IIb 期临床试验中获得的安全性和疗效数据。还讨论了古巴开展的针对儿童和成人脑胶质瘤使用尼妥珠单抗的上市后监测数据。总的来说，尼妥珠单抗在上皮来源的癌症中具有巨大的治疗潜力。
相似文献
1
Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin.尼妥珠单抗，一种有前景的治疗上皮来源肿瘤的治疗性单克隆抗体。
MAbs. 2009 Jan-Feb;1(1):41-8. doi: 10.4161/mabs.1.1.7509.
2
Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients.尼妥珠单抗为不可切除的晚期头颈部鳞状细胞癌患者带来生存获益：一项针对印度患者的随机、开放标签、IIb期、为期5年的研究。
Oral Oncol. 2014 May;50(5):498-505. doi: 10.1016/j.oraloncology.2013.11.008. Epub 2014 Mar 6.
3
Promising new molecular targeted therapies in head and neck cancer.头颈部癌症的有前途的新型分子靶向治疗方法。
Drugs. 2013 Mar;73(4):315-25. doi: 10.1007/s40265-013-0025-3.
4
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck.一项开放标签、单臂、II 期临床试验，评估 zalutumumab（一种人源化抗 EGFR 单克隆抗体）在铂类耐药的头颈部鳞状细胞癌患者中的疗效。
Cancer Chemother Pharmacol. 2014 Jun;73(6):1227-39. doi: 10.1007/s00280-014-2459-z. Epub 2014 Apr 9.
5
Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model.尼妥珠单抗增强光动力疗法在口腔肿瘤模型中的抗肿瘤作用。
Oncotarget. 2015 May 30;6(15):13487-505. doi: 10.18632/oncotarget.3622.
6
The role of cetuximab in the treatment of squamous cell cancer of the head and neck.西妥昔单抗在头颈部鳞状细胞癌治疗中的作用。
Expert Opin Biol Ther. 2005 Aug;5(8):1085-93. doi: 10.1517/14712598.5.8.1085.
7
Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck.针对头颈部鳞状细胞癌中的表皮生长因子受体信号传导
Br J Cancer. 2007 Feb 12;96(3):408-16. doi: 10.1038/sj.bjc.6603566. Epub 2007 Jan 16.
8
Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.尼妥珠单抗治疗局部晚期头颈部鳞癌的药效学研究：SENDO 基金会研究。
Clin Cancer Res. 2010 Apr 15;16(8):2474-82. doi: 10.1158/1078-0432.CCR-09-3042. Epub 2010 Apr 6.
9
A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies.尼妥珠单抗（一种针对表皮生长因子受体的抗体）治疗晚期实体瘤患者的剂量递增 I 期临床试验。
Invest New Drugs. 2011 Oct;29(5):996-1003. doi: 10.1007/s10637-010-9444-0. Epub 2010 May 8.
10
Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck.尼妥珠单抗联合放疗治疗不可切除的头颈部鳞状细胞癌。
Cancer Biol Ther. 2010 Mar 1;9(5):343-9. doi: 10.4161/cbt.9.5.10981. Epub 2010 Mar 20.
引用本文的文献
1
Unravelling molecular mechanism of oral squamous cell carcinoma and genetic landscape: an insight into disease complexity, available therapies, and future considerations.揭示口腔鳞状细胞癌的分子机制和基因图谱：洞察疾病复杂性、现有治疗方法及未来考量
Front Immunol. 2025 Aug 13;16:1626243. doi: 10.3389/fimmu.2025.1626243. eCollection 2025.
2
Nimotuzumab plus chemotherapy and immunotherapy as first-line/neoadjuvant therapy for advanced esophageal squamous cell carcinoma.尼妥珠单抗联合化疗及免疫疗法作为晚期食管鳞状细胞癌的一线/新辅助治疗
Front Pharmacol. 2025 Jul 2;16:1585048. doi: 10.3389/fphar.2025.1585048. eCollection 2025.
3
Prognostic analysis of nimotuzumab combined with concurrent chemoradiotherapy for locally advanced cervical cancer: a multicenter real-world study.尼妥珠单抗联合同步放化疗治疗局部晚期宫颈癌的预后分析：一项多中心真实世界研究
Sci Rep. 2025 May 7;15(1):15877. doi: 10.1038/s41598-025-98359-4.
4
Efficacy and safety of molecular targeted therapies in nasopharyngeal carcinoma: a network meta-analysis.分子靶向治疗在鼻咽癌中的疗效与安全性：一项网状Meta分析
BMC Cancer. 2025 Jan 21;25(1):110. doi: 10.1186/s12885-025-13528-y.
5
Coley's Toxin to First Approved Therapeutic Vaccine-A Brief Historical Account in the Progression of Immunobiology-Based Cancer Treatment.科利毒素到首个获批的治疗性疫苗——基于免疫生物学的癌症治疗进展简史
Biomedicines. 2024 Nov 30;12(12):2746. doi: 10.3390/biomedicines12122746.
6
Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer.探索联合靶向表皮生长因子受体（EGFR）和纺锤体组装检查点通路在口腔癌中的治疗意义
Pharmaceutics. 2024 Sep 11;16(9):1196. doi: 10.3390/pharmaceutics16091196.
7
Nimotuzumab combined with radiotherapy+/- chemotherapy for definitive treatment of locally advanced squamous cell carcinoma of head and neck: a metanalysis of randomized controlled trials.尼妥珠单抗联合放疗±化疗用于局部晚期头颈部鳞状细胞癌的根治性治疗：一项随机对照试验的荟萃分析
Front Oncol. 2024 Jun 13;14:1380428. doi: 10.3389/fonc.2024.1380428. eCollection 2024.
8
Concurrent nimotuzumab and intensity-modulated radiotherapy for elderly patients with locally advanced nasopharyngeal carcinoma.尼妥珠单抗联合调强放疗治疗老年局部晚期鼻咽癌的临床观察
Cancer Sci. 2024 Aug;115(8):2729-2737. doi: 10.1111/cas.16213. Epub 2024 May 28.
9
Evaluation of Advanced Nanomaterials for Cancer Diagnosis and Treatment.用于癌症诊断与治疗的先进纳米材料评估
Pharmaceutics. 2024 Mar 28;16(4):473. doi: 10.3390/pharmaceutics16040473.
10
Efficacy and Safety of Nimotuzumab in Combination with Radiotherapy or Chemoradiotherapy for Local Advanced Head and Neck Cancer: A Systematic Review and Meta-analysis.尼妥珠单抗联合放疗或放化疗治疗局部晚期头颈部癌的疗效和安全性的系统评价和荟萃分析。
Curr Cancer Drug Targets. 2024;24(9):952-966. doi: 10.2174/0115680096281982240117114819.
本文引用的文献
1
EGFR antagonists in cancer treatment.癌症治疗中的表皮生长因子受体拮抗剂
N Engl J Med. 2008 Mar 13;358(11):1160-74. doi: 10.1056/NEJMra0707704.
2
Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities.不同亲和力的抗表皮生长因子受体单克隆抗体的体外生物学活性
Hybridoma (Larchmt). 2007 Dec;26(6):423-31. doi: 10.1089/hyb.2007.0516.
3
Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti- epidermal growth factor receptor monoclonal antibody Nimotuzumab.用高静脉剂量的抗表皮生长因子受体单克隆抗体尼妥珠单抗对埃塞俄比亚长尾猴进行26周治疗后的全身和皮肤毒性。
Cancer Biol Ther. 2007 Sep;6(9):1390-5. doi: 10.4161/cbt.6.9.4539. Epub 2007 Jun 5.
4
Incidence and management of cutaneous toxicities associated with cetuximab.西妥昔单抗相关皮肤毒性的发生率及管理
Expert Opin Drug Saf. 2007 Mar;6(2):175-82. doi: 10.1517/14740338.6.2.175.
5
Panitumumab the first fully human monoclonal antibody: from the bench to the clinic.帕尼单抗——首个完全人源化单克隆抗体：从实验室到临床应用
Anticancer Drugs. 2007 Jan;18(1):7-15. doi: 10.1097/CAD.0b013e32800feecb.
6
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.与表皮生长因子受体抑制剂相关的皮肤副作用。
J Am Acad Dermatol. 2006 Oct;55(4):657-70. doi: 10.1016/j.jaad.2005.10.010.
7
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.放疗联合西妥昔单抗治疗头颈部鳞状细胞癌。
N Engl J Med. 2006 Feb 9;354(6):567-78. doi: 10.1056/NEJMoa053422.
8
Nimotuzumab: evidence of clinical benefit without rash.尼妥珠单抗：无皮疹的临床获益证据。
Oncologist. 2005 Oct;10(9):760-1. doi: 10.1634/theoncologist.10-9-760.
9
Recent developments related to the EGFR as a target for cancer chemotherapy.表皮生长因子受体作为癌症化疗靶点的相关最新进展。
Curr Opin Pharmacol. 2005 Aug;5(4):343-9. doi: 10.1016/j.coph.2005.02.007.
10
ERBB receptors and cancer: the complexity of targeted inhibitors.ERBB受体与癌症：靶向抑制剂的复杂性
Nat Rev Cancer. 2005 May;5(5):341-54. doi: 10.1038/nrc1609.
Zotero 插件